SG11201500787YA - Pyrazolopyrimidine compounds - Google Patents
Pyrazolopyrimidine compoundsInfo
- Publication number
- SG11201500787YA SG11201500787YA SG11201500787YA SG11201500787YA SG11201500787YA SG 11201500787Y A SG11201500787Y A SG 11201500787YA SG 11201500787Y A SG11201500787Y A SG 11201500787YA SG 11201500787Y A SG11201500787Y A SG 11201500787YA SG 11201500787Y A SG11201500787Y A SG 11201500787YA
- Authority
- SG
- Singapore
- Prior art keywords
- pyrazolopyrimidine compounds
- pyrazolopyrimidine
- compounds
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261692853P | 2012-08-24 | 2012-08-24 | |
| US201361774094P | 2013-03-07 | 2013-03-07 | |
| PCT/US2013/056107 WO2014031815A1 (en) | 2012-08-24 | 2013-08-22 | Pyrazolopyrimidine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201500787YA true SG11201500787YA (en) | 2015-03-30 |
Family
ID=49085221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201500787YA SG11201500787YA (en) | 2012-08-24 | 2013-08-22 | Pyrazolopyrimidine compounds |
Country Status (26)
| Country | Link |
|---|---|
| US (5) | US9173872B2 (en) |
| EP (1) | EP2888264B1 (en) |
| JP (1) | JP6196674B2 (en) |
| KR (1) | KR20150046267A (en) |
| CN (1) | CN104755480B (en) |
| AR (1) | AR092198A1 (en) |
| AU (1) | AU2013305790B2 (en) |
| BR (1) | BR112015003259A2 (en) |
| CA (1) | CA2880576A1 (en) |
| CL (1) | CL2015000408A1 (en) |
| CR (1) | CR20150061A (en) |
| DO (1) | DOP2015000027A (en) |
| EA (1) | EA026354B1 (en) |
| ES (1) | ES2653254T3 (en) |
| HK (1) | HK1211029A1 (en) |
| IL (1) | IL236983B (en) |
| MX (1) | MX359671B (en) |
| MY (1) | MY175676A (en) |
| NZ (1) | NZ704224A (en) |
| PE (1) | PE20150730A1 (en) |
| PH (1) | PH12015500401A1 (en) |
| SG (1) | SG11201500787YA (en) |
| TW (1) | TWI625331B (en) |
| UA (1) | UA114109C2 (en) |
| UY (1) | UY34987A (en) |
| WO (1) | WO2014031815A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103195C2 (en) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| WO2013014052A1 (en) | 2011-07-22 | 2013-01-31 | Glaxosmithkline Llc | Composition |
| EP2888264B1 (en) | 2012-08-24 | 2017-09-27 | Glaxosmithkline LLC | Pyrazolopyrimidine compounds |
| BR112015011439A2 (en) | 2012-11-20 | 2017-07-11 | Glaxosmithkline Llc | compound, pharmaceutical composition, vaccine composition, and use of a compound |
| ES2632448T3 (en) | 2012-11-20 | 2017-09-13 | Glaxosmithkline Llc | New compounds |
| HUE13857477T2 (en) | 2012-11-20 | 2018-05-28 | Glaxosmithkline Llc | Novel compounds |
| WO2019209811A1 (en) | 2018-04-24 | 2019-10-31 | Bristol-Myers Squibb Company | Macrocyclic toll-like receptor 7 (tlr7) agonists |
| US11554120B2 (en) | 2018-08-03 | 2023-01-17 | Bristol-Myers Squibb Company | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor |
| CN110772523B (en) * | 2019-11-07 | 2020-06-26 | 黑龙江中医药大学 | A pharmaceutical composition for preventing and treating nephropathy |
| JP2023512208A (en) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | 1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists |
| KR20220132592A (en) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists |
| WO2021154665A1 (en) | 2020-01-27 | 2021-08-05 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| KR20220132601A (en) | 2020-01-27 | 2022-09-30 | 브리스톨-마이어스 스큅 컴퍼니 | 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists |
| EP4097100A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| US20230122249A1 (en) | 2020-01-27 | 2023-04-20 | Bristol-Myers Squibb Company | 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS |
| EP4097103A1 (en) | 2020-01-27 | 2022-12-07 | Bristol-Myers Squibb Company | 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists |
| JP2023512205A (en) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | 1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists |
| JP2023512230A (en) | 2020-01-27 | 2023-03-24 | ブリストル－マイヤーズ スクイブ カンパニー | C3-substituted 1H-pyrazolo[4,3-d]pyrimidine compounds as Toll-like receptor 7 (TLR7) agonists |
Family Cites Families (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW574214B (en) | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
| US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US7125880B1 (en) | 1995-06-06 | 2006-10-24 | Pfizer Inc. | Corticotropin releasing factor antagonists |
| AU3176297A (en) | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| TW572758B (en) | 1997-12-22 | 2004-01-21 | Sumitomo Pharma | Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| CZ27399A3 (en) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituted nitrogen heterocyclic derivatives process of their preparation, the derivatives employed as medicaments, pharmaceutical composition and a compound pharmaceutical preparation in which these derivatives are comprised as well as use of these derivatives for preparing medicaments |
| IL150594A0 (en) | 2000-01-07 | 2003-02-12 | Ustav Ex Botan Adademie Ved Ce | Purine derivatives, process for their preparation and use |
| CN101016296A (en) | 2000-04-28 | 2007-08-15 | 阿卡蒂亚药品公司 | Muscarinic agonists |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| TW200301251A (en) | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
| ATE478872T1 (en) | 2002-03-28 | 2010-09-15 | Ustav Ex Botan Av Cr V V I I O | PYRAZOLOA4,3-DÜPYRIMIDINES, METHOD FOR THE PRODUCTION THEREOF AND THERAPEUTIC USE |
| KR20050006221A (en) | 2002-05-06 | 2005-01-15 | 제네랩스 테크놀로지스, 인코포레이티드 | Nucleoside derivatives for treating hepatitis c virus infection |
| US6713241B2 (en) | 2002-08-09 | 2004-03-30 | Eastman Kodak Company | Thermally developable emulsions and imaging materials containing binder mixture |
| US7553839B2 (en) | 2002-08-21 | 2009-06-30 | Industrial Research Limited | 5h-pyrrolo[3,2-D] pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| AU2003271064B2 (en) | 2002-09-27 | 2010-06-17 | Dainippon Sumitomo Pharma Co., Ltd. | Novel adenine compound and use thereof |
| CN1816530A (en) | 2003-07-01 | 2006-08-09 | 麦克公司 | Opthalmic compositions for treating ocular hypertension |
| US20070161582A1 (en) | 2003-08-08 | 2007-07-12 | Dusan Mijikovic | Pharmaceutical compositions and methods for metabolic modulation |
| ES2342069T4 (en) | 2003-09-05 | 2011-01-26 | Anadys Pharmaceuticals, Inc. | TLR7 LINKS FOR THE TREATMENT OF HEPATITIS C. |
| KR101494056B1 (en) | 2003-10-03 | 2015-02-16 | 쓰리엠 이노베이티브 프로퍼티즈 컴파니 | Pyrazolopyridines and analogs thereof |
| WO2005092892A1 (en) | 2004-03-26 | 2005-10-06 | Dainippon Sumitomo Pharma Co., Ltd. | 8-oxoadenine compound |
| CA2559036C (en) * | 2004-03-26 | 2013-08-20 | Dainippon Sumitomo Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| TWI378934B (en) | 2004-04-02 | 2012-12-11 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| MXPA06013250A (en) | 2004-05-14 | 2007-02-28 | Abbott Lab | Kinase inhibitors as therapeutic agents. |
| JP2007530579A (en) * | 2004-06-10 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | Amide-substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| US20060029642A1 (en) | 2004-08-03 | 2006-02-09 | Dusan Miljkovic | Methods and compositions for improved chromium complexes |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| JP2008540396A (en) | 2005-05-04 | 2008-11-20 | ファイザー・リミテッド | 2-Amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for treating viral infections such as cancer and hepatitis C |
| NZ540160A (en) * | 2005-05-20 | 2008-03-28 | Einstein Coll Med | Inhibitors of nucleoside phosphorylases |
| JPWO2006126718A1 (en) * | 2005-05-27 | 2008-12-25 | 田辺三菱製薬株式会社 | Pyrazolopyrimidine derivatives |
| JP2009502801A (en) * | 2005-07-22 | 2009-01-29 | サネシス ファーマシューティカルズ， インコーポレイテッド | Pyrazolopyrimidines useful as Aurora kinase inhibitors |
| WO2007024707A2 (en) | 2005-08-22 | 2007-03-01 | The Regents Of The University Of California | Tlr agonists |
| US8003624B2 (en) | 2005-08-25 | 2011-08-23 | Schering Corporation | Functionally selective ALPHA2C adrenoreceptor agonists |
| RU2008110908A (en) | 2005-08-25 | 2009-09-27 | Шеринг Корпорейшн (US) | IMIDAZOLE DERIVATIVES AS A FUNCTIONALLY SELECTIVE ALFA-2C ADRENORE RECEPTORS |
| AU2006287157A1 (en) | 2005-09-02 | 2007-03-08 | Pfizer Inc. | Hydroxy substituted 1H-imidazopyridines and methods |
| TW200801003A (en) | 2005-09-16 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| EP1939199A4 (en) | 2005-09-22 | 2010-10-20 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
| EP1939200A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
| JPWO2007034881A1 (en) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | New adenine compounds |
| EP1939201A4 (en) | 2005-09-22 | 2010-06-16 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
| JPWO2007034817A1 (en) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | New adenine compounds |
| TW200745114A (en) | 2005-09-22 | 2007-12-16 | Astrazeneca Ab | Novel compounds |
| CN1947717B (en) | 2005-10-14 | 2012-09-26 | 卓敏 | Method for treating neuronal and non-neuronal pain |
| ES2374455T3 (en) | 2006-02-17 | 2012-02-16 | Pfizer Limited | DERIVATIVES OF 3-DEAZAPURINZA AS MODULATORS OF TLR7. |
| BRPI0709145A2 (en) | 2006-03-24 | 2011-06-28 | Siemens Ag | method for operating a compressor unit, and an associated compressor unit |
| CA2680789C (en) | 2006-03-28 | 2016-02-16 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| GB0610666D0 (en) | 2006-05-30 | 2006-07-05 | Glaxo Group Ltd | Fluid dispenser |
| EP2029597A4 (en) | 2006-05-31 | 2011-11-23 | Univ California | Purine analogs |
| JP2009542645A (en) | 2006-07-05 | 2009-12-03 | アストラゼネカ・アクチエボラーグ | 8-oxoadenine derivatives acting as modulators of TLR7 |
| PL2038290T3 (en) | 2006-07-07 | 2014-03-31 | Gilead Sciences Inc | Modulators of toll-like receptor 7 |
| TW200831105A (en) | 2006-12-14 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| DK2125792T3 (en) | 2007-02-19 | 2011-03-07 | Glaxosmithkline Llc | Purine derivatives as immunomodulators |
| EP2132209B8 (en) | 2007-03-19 | 2014-04-16 | AstraZeneca AB | 9-substituted-8-oxo-adenine compounds as toll-like receptor (tlr7 ) modulators |
| ES2373616T3 (en) | 2007-03-19 | 2012-02-07 | Astrazeneca Ab | 8-OXO-ADENINE 9 COMPOUNDS REPLACED AS TOLL TYPE RECEIVER MODULATORS (TLR7). |
| PE20081887A1 (en) | 2007-03-20 | 2009-01-16 | Dainippon Sumitomo Pharma Co | NEW ADENINE COMPOUND |
| EP2138497A4 (en) | 2007-03-20 | 2012-01-04 | Dainippon Sumitomo Pharma Co | Novel adenine compound |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| CN101784548B (en) | 2007-06-29 | 2013-07-17 | 吉里德科学公司 | Purine derivatives and their use as modulators of Toll-like receptor 7 |
| GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| CN101842098A (en) | 2007-08-10 | 2010-09-22 | 基因实验室技术有限公司 | The nitrogenous bicyclo-chemical entities that is used for the treatment of viral infection |
| UY31531A1 (en) | 2007-12-17 | 2009-08-03 | SALTS DERIVED FROM 8-OXOADENINE PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THERAPY AS TOLL TYPE RECEIVER MODULATORS (TLR) | |
| WO2009151910A2 (en) | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| US8946239B2 (en) | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
| EP2324025A1 (en) | 2008-08-11 | 2011-05-25 | Smithkline Beecham Corporation | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| US8802684B2 (en) | 2008-08-11 | 2014-08-12 | Glaxosmithkline Llc | Adenine derivatives |
| BRPI0917013A2 (en) | 2008-08-11 | 2016-02-16 | Glaxosmithkline Llc | methods for treating allergic diseases and other inflammatory conditions, and for treating or preventing disease, compound, pharmaceutical composition, and use of a compound |
| WO2010018132A1 (en) | 2008-08-11 | 2010-02-18 | Smithkline Beecham Corporation | Compounds |
| EP2326646B1 (en) | 2008-08-11 | 2013-07-31 | GlaxoSmithKline LLC | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| UA103195C2 (en) | 2008-08-11 | 2013-09-25 | Глаксосмитклайн Ллк | Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases |
| CN102548999A (en) | 2009-01-20 | 2012-07-04 | 山东轩竹医药科技有限公司 | Cephalosporin derivatives containing substituted nitrogen-containing fused heterocyclic ring |
| EA023536B1 (en) | 2009-08-07 | 2016-06-30 | Глаксосмитклайн Байолоджикалс Са | Oxoadenine derivatives conjugated with phospho- or phosphonolipids |
| US8703754B2 (en) | 2010-02-10 | 2014-04-22 | Glaxosmithkline Llc | 6-amino-2-{[(1S)-1-methylbutyl]oxy}-9-[5-(1-piperidinyl)-7,9-dihydro-8H-purin-8-one maleate |
| JP2013519644A (en) | 2010-02-10 | 2013-05-30 | グラクソスミスクライン エルエルシー | Purine derivatives and their pharmaceutical use |
| WO2012009258A2 (en) | 2010-07-13 | 2012-01-19 | Edward Roberts | Peptidomimetic galanin receptor modulators |
| WO2012092552A1 (en) | 2010-12-30 | 2012-07-05 | Selecta Biosciences, Inc. | Synthetic nanocarriers with reactive groups that release biologically active agents |
| AU2012212323A1 (en) | 2011-02-01 | 2013-09-12 | The Board Of Trustees Of The University Of Illinois | HDAC inhibitors and therapeutic methods using the same |
| EP2670244B1 (en) | 2011-02-04 | 2018-04-11 | Duquesne University of The Holy Spirit | Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient |
| WO2013014052A1 (en) | 2011-07-22 | 2013-01-31 | Glaxosmithkline Llc | Composition |
| EP2888264B1 (en) * | 2012-08-24 | 2017-09-27 | Glaxosmithkline LLC | Pyrazolopyrimidine compounds |
| ES2632448T3 (en) | 2012-11-20 | 2017-09-13 | Glaxosmithkline Llc | New compounds |
| HUE13857477T2 (en) | 2012-11-20 | 2018-05-28 | Glaxosmithkline Llc | Novel compounds |
| BR112015011439A2 (en) | 2012-11-20 | 2017-07-11 | Glaxosmithkline Llc | compound, pharmaceutical composition, vaccine composition, and use of a compound |
| CA2938476A1 (en) | 2014-02-20 | 2015-08-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyrrolo[3,2-d]pyrimidine derivatives as inducers of human interferon |
-
2013
- 2013-08-22 EP EP13756249.2A patent/EP2888264B1/en active Active
- 2013-08-22 PE PE2015000238A patent/PE20150730A1/en active IP Right Grant
- 2013-08-22 US US13/973,466 patent/US9173872B2/en active Active
- 2013-08-22 EA EA201590189A patent/EA026354B1/en not_active IP Right Cessation
- 2013-08-22 UY UY0001034987A patent/UY34987A/en not_active Application Discontinuation
- 2013-08-22 MY MYPI2015700519A patent/MY175676A/en unknown
- 2013-08-22 BR BR112015003259A patent/BR112015003259A2/en not_active Application Discontinuation
- 2013-08-22 NZ NZ704224A patent/NZ704224A/en not_active IP Right Cessation
- 2013-08-22 UA UAA201501077A patent/UA114109C2/en unknown
- 2013-08-22 AR ARP130102974 patent/AR092198A1/en unknown
- 2013-08-22 TW TW102130088A patent/TWI625331B/en not_active IP Right Cessation
- 2013-08-22 US US14/423,400 patent/US9555036B2/en active Active
- 2013-08-22 AU AU2013305790A patent/AU2013305790B2/en not_active Ceased
- 2013-08-22 MX MX2015002433A patent/MX359671B/en active IP Right Grant
- 2013-08-22 CN CN201380055759.3A patent/CN104755480B/en not_active Expired - Fee Related
- 2013-08-22 JP JP2015528644A patent/JP6196674B2/en not_active Expired - Fee Related
- 2013-08-22 WO PCT/US2013/056107 patent/WO2014031815A1/en active Application Filing
- 2013-08-22 SG SG11201500787YA patent/SG11201500787YA/en unknown
- 2013-08-22 CA CA2880576A patent/CA2880576A1/en not_active Abandoned
- 2013-08-22 KR KR1020157007428A patent/KR20150046267A/en not_active Application Discontinuation
- 2013-08-22 ES ES13756249.2T patent/ES2653254T3/en active Active
-
2015
- 2015-01-29 IL IL236983A patent/IL236983B/en active IP Right Grant
- 2015-02-09 CR CR20150061A patent/CR20150061A/en unknown
- 2015-02-12 DO DO2015000027A patent/DOP2015000027A/en unknown
- 2015-02-20 CL CL2015000408A patent/CL2015000408A1/en unknown
- 2015-02-24 PH PH12015500401A patent/PH12015500401A1/en unknown
- 2015-10-01 US US14/872,620 patent/US9662336B2/en not_active Expired - Fee Related
- 2015-12-02 HK HK15111867.0A patent/HK1211029A1/en unknown
-
2017
- 2017-04-26 US US15/497,852 patent/US10022442B2/en active Active
-
2018
- 2018-06-14 US US16/008,421 patent/US20180289800A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181041T1 (en) | Pyrazolopyrimidine compounds | |
| HK1208444A1 (en) | Pyrrolobenzodiazepines | |
| HK1208217A1 (en) | Pyrrolobenzodiazepines | |
| HK1211029A1 (en) | Pyrazolopyrimidine compounds | |
| HK1203498A1 (en) | Tetrahydropyrazolopyrimidine compounds | |
| HK1198761A1 (en) | Imidazopyrrolidinone compounds | |
| EP2925129A4 (en) | Pro-neurogenic compounds | |
| GB201209138D0 (en) | Compounds | |
| GB201214750D0 (en) | Compounds | |
| GB201215357D0 (en) | Compounds | |
| EP2887803A4 (en) | Pro-neurogenic compounds | |
| EP2828262A4 (en) | Imidazotriazinone compounds | |
| GB201204985D0 (en) | Compounds | |
| GB201204125D0 (en) | Compounds | |
| ME02404B (en) | Tetrahydropyrrolothiazine compounds | |
| GB201219820D0 (en) | Compounds | |
| GB201217310D0 (en) | Compounds | |
| GB201223429D0 (en) | Compounds | |
| GB201220029D0 (en) | Compounds | |
| GB201219819D0 (en) | Compounds | |
| GB201218799D0 (en) | Compounds | |
| GB201218776D0 (en) | Compounds | |
| GB201218758D0 (en) | Compounds | |
| GB201218774D0 (en) | Compounds | |
| GB201218018D0 (en) | Compounds |